Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anhui Anke Biotechnology (Group) Co's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was ¥197 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥784 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Anhui Anke Biotechnology (Group) Co's annualizedROC % for the quarter that ended in Mar. 2026 was 19.20%.
Anhui Anke Biotechnology (Group) Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 43.19%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Anhui Anke Biotechnology (Group) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.85%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Anke Biotechnology (Group) Co EBIT Related Terms
Anhui Anke Biotechnology (Group) Co EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anhui Anke Biotechnology (Group) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anhui Anke Biotechnology (Group) Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anhui Anke Biotechnology (Group) Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Anhui Anke Biotechnology (Group) Co's EV-to-EBIT falls into.
Anhui Anke Biotechnology (Group) Co EBIT Calculation
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥784 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anhui Anke Biotechnology (Group) Co (SZSE:300009) has a EBIT of ¥784 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anhui Anke Biotechnology (Group) Co.
Is Anhui Anke Biotechnology (Group) Co's EBIT too high?
Anhui Anke Biotechnology (Group) Co's current EBIT is ¥784 Mil. Overall, Anhui Anke Biotechnology (Group) Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anhui Anke Biotechnology (Group) Co's EBIT compare to VRTX and REGN?
Anhui Anke Biotechnology (Group) Co's EBIT of ¥784 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anhui Anke Biotechnology (Group) Co. Anhui Anke Biotechnology (Group) Co's current EBIT is ¥784 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anhui Anke Biotechnology (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co (SZSE:300009) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.72, compared to a current price of ¥8.73 — trading 18.6% below its estimated fair value. The current EBIT is ¥784 Mil. Anhui Anke Biotechnology (Group) Co's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anhui Anke Biotechnology (Group) Co (SZSE:300009), the current EBIT is ¥784 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anhui Anke Biotechnology (Group) Co (SZSE:300009) Overvalued in 2026?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co stock appears to be undervalued.
The current stock price of ¥8.73 is trading 18.6% below its estimated GF Value™ of ¥10.72.
GuruFocus considers Anhui Anke Biotechnology (Group) Co to be Modestly Undervalued.
Key valuation signals for SZSE:300009:
EBIT: ¥784 Mil
GF Value™: ¥10.72 vs. price of ¥8.73 (18.6% below fair value)
No single metric tells the full story. See the SZSE:300009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
90GF Score
Get the complete analysis for SZSE:300009
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300009 has been successfully added to your 
